Skip to content

Marjorie R. Levinstein

2 papers in the library · 49 citations · publishing 2024-2025

Papers

Sort Most recent Most cited

Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?

The American journal of psychiatry March 1, 2025 Marjorie R Levinstein, Reece C Budinich, Jordi Bonaventura et al. 49 citations

Ketamine is a racemic compound and medication comprised of (S)-ketamine and (R)-ketamine enantiomers and its metabolites. It has been used for decades as a dissociative anesthetic, analgesic, and recreational drug. More recently, ketamine, its enantiomers, and its metabolites have been used or are being investigated for the treatment of refractory depression, as well as for comorbid disorders...

Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats

Nature Communications January 30, 2024 Tommaso di Ianni, Sedona N. Ewbank, Marjorie R. Levinstein et al.

Subanesthetic ketamine is increasingly used for the treatment of varied psychiatric conditions, both on- and off-label. While it is commonly classified as an N -methyl D-aspartate receptor (NMDAR) antagonist, our picture of ketamine’s mechanistic underpinnings is incomplete. Recent clinical evidence has indicated, controversially, that a component of the efficacy of subanesthetic ketamine may...